In the BioHarmony Drug Report Database
Trimetrexate glucuronate
Neutrexin (trimetrexate glucuronate) is a small molecule pharmaceutical. Trimetrexate glucuronate was first approved as Neutrexin on 1993-12-17. It is used to treat pneumocystis pneumonia in the USA. It is known to target dihydrofolate reductase.
Trade Name
|
Neutrexin |
|---|---|
Common Name
|
trimetrexate glucuronate |
ChEMBL ID
|
CHEMBL2218878 |
Indication
|
pneumocystis pneumonia |
Drug Class
|
Antimetabolites (folic acid derivatives) |
Image (chem structure or protein)